(Q53654363)

16 May 2018

title

Small molecule inhibitors of EZH2: the emerging translational landscape. (English)

1 reference

16 May 2018

author name string

Heike Keilhack

series ordinal

1

1 reference

16 May 2018

Jesse J Smith

series ordinal

2

1 reference

16 May 2018

publication date

1 January 2015

1 reference

16 May 2018

published in

Epigenomics

1 reference

16 May 2018

volume

7

1 reference

16 May 2018

issue

3

1 reference

16 May 2018

page(s)

337-341

1 reference

16 May 2018

The Polycomb complex PRC2 and its mark in life

cites work

1 reference

Regulation and Role of EZH2 in Cancer

21 January 2018

1 reference

A complex Polycomb issue: the two faces of EZH2 in cancer

21 January 2018

1 reference

PRC2 is recurrently inactivated through EED or SUZ12 loss in malignant peripheral nerve sheath tumors.

21 January 2018

1 reference

Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin

21 January 2018

1 reference

EZH2 Y641 mutations in follicular lymphoma.

21 January 2018

1 reference

Coordinated activities of wild-type plus mutant EZH2 drive tumor-associated hypertrimethylation of lysine 27 on histone H3 (H3K27) in human B-cell lymphomas

21 January 2018

1 reference

Somatic mutations at EZH2 Y641 act dominantly through a mechanism of selectively altered PRC2 catalytic activity, to increase H3K27 trimethylation

21 January 2018

1 reference

EZH2 inhibitor efficacy in non-Hodgkin's lymphoma does not require suppression of H3K27 monomethylation.

21 January 2018

1 reference

Selective inhibition of EZH2 by EPZ-6438 leads to potent antitumor activity in EZH2-mutant non-Hodgkin lymphoma

21 January 2018

1 reference

EZH2 is required for germinal center formation and somatic EZH2 mutations promote lymphoid transformation

21 January 2018

1 reference

EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations

21 January 2018

1 reference

Identification of Potent, Selective, Cell-Active Inhibitors of the Histone Lysine Methyltransferase EZH2.

21 January 2018

1 reference

Selective inhibition of Ezh2 by a small molecule inhibitor blocks tumor cells proliferation

21 January 2018

1 reference

An orally bioavailable chemical probe of the Lysine Methyltransferases EZH2 and EZH1

21 January 2018

1 reference

Synergistic Anti-Tumor Activity of EZH2 Inhibitors and Glucocorticoid Receptor Agonists in Models of Germinal Center Non-Hodgkin Lymphomas

21 January 2018

1 reference

A remarkably simple genome underlies highly malignant pediatric rhabdoid cancers

21 January 2018

1 reference

Epigenetic antagonism between polycomb and SWI/SNF complexes during oncogenic transformation

21 January 2018

1 reference

Durable tumor regression in genetically altered malignant rhabdoid tumors by inhibition of methyltransferase EZH2.

21 January 2018

1 reference

The expanding family of SMARCB1(INI1)-deficient neoplasia: implications of phenotypic, biological, and molecular heterogeneity

21 January 2018

1 reference

The tumour microenvironment in B cell lymphomas

21 January 2018

1 reference

Inflammation-induced repression of chromatin bound by the transcription factor Foxp3 in regulatory T cells

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.2217/EPI.15.14

1 reference

16 May 2018

1 reference

16 May 2018